Please assess the completion status of the following clinical trial:

Trial Title: CoStar Catheter System Evaluation

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is ≥18 years of age.~2. Eligible for percutaneous coronary intervention (PCI).~3. Documented stable or unstable angina pectoris (Canadian Cardiovascular Society Classification \[CCS\] 1, 2, 3, or 4), documented ischemia, or documented silent ischemia.~4. Left ventricular ejection fraction (LVEF) ≥25% documented within the last 6 weeks.~5. Acceptable candidate for coronary artery bypass graft surgery (CABG).~6. Patient understands the study requirements and the treatment procedures and provides written Informed Consent using a form that has been approved by the local Institutional Review Board or Ethics Committee before any study-specific tests or procedures are performed.~7. Willing to comply with all specified follow-up evaluations.~Inclusion Criteria (Angiographic):~1. A single de novo lesion per study subject may be treated with the study device.~2. Each target lesion may be composed of multiple lesions but must be completely coverable by one (1) study stent.~3. Cumulative target lesion length per vessel is ≤24 mm based on a visual estimate.~4. RVD of ≥2.5 mm to ≤3.0 mm based on a visual estimate.~5. Target lesion diameter stenosis ≥50% and \<100% based on a visual estimate.~6. Target vessel has not undergone prior revascularization within the preceding 6 months.~7. Target lesion must be a minimum of 10 mm distance from any previously treated segment of the target vessel~Exclusion Criteria:~1. Known sensitivity to cobalt chromium, paclitaxel or polymeric matrices: PLGA.~2. Planned treatment with any other PCI device in the target vessel(s).~3. Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q wave, or creatinine kinase (CK) \>2 times the laboratory upper limits of normal and elevated MB.~4. The patient is in cardiogenic shock.~5. Cerebrovascular Accident (CVA) within the past 6 months.~6. Acute or chronic renal dysfunction (creatinine \>2.0 mg/dl or \>150 µmol/L).~7. Contraindication to ASA or to clopidogrel.~8. Thrombocytopenia (platelet count \<100, 000/mm3).~9. Active gastrointestinal (GI) bleeding within the past three months.~10. Any prior true anaphylactic reaction to contrast agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- OTW Catheter System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).